Treatment News : Incivek Improves Outcomes for HIV/HCV Coinfected Gay Men

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » November 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 14, 2013

Incivek Improves Outcomes for HIV/HCV Coinfected Gay Men

Adding Incivek (telaprevir) to a regimen of pegylated interferon and ribavirin both shortens the treatment duration and raises cure rates among gay, HIV-positive men coinfected with acute hepatitis C virus (HCV), aidsmap reports. Daniel Fierer, MD, of Mount Sinai Medical Center, presented findings from an open-label pilot study at the 64th Annual Meeting of the American Association of the Study of Liver Diseases (AASLD) in Washington, DC.

The study included two groups of sexually active HIV-positive men who have sex with men (MSM) with genotype 1 of hep C who were identified as having acute hep C through an elevated routine liver enzyme test or a newly detectable hep C viral load screen. The investigators first observed the men for several weeks to determine if they would spontaneously clear the hep C virus. If the participants did not, they were given a regimen of Incivek, pegylated interferon alfa-2a and ribavirin for 12 weeks, beginning within half a year of their first recorded elevated liver enzyme.

Sixteen out of 19 participants (84 percent) in the first group of men taking triple therapy achieved a sustained virologic response (SVR, considered a cure) 12 weeks after completing therapy. Six out of seven of the men in the second group who had sufficient follow-up achieved an SVR. The combined results between the two groups yielded an overall SVR rate of 85 percent.

The study also had a comparator group of 48 HIV-positive MSM with genotype 1 of hep C who received 24 weeks of treatment with just interferon and ribavirin. Thirty men (63 percent) achieved an SVR.

Although the difference in the SVR rates between the triple and double combination treatment groups was just under the level of statistical significance, meaning the difference may have been caused by chance, Fierer still concluded that the addition of Incivek improves cure rates in this population.

The regimens proved well tolerated.

Fierer acknowledged Incivek’s swan song status as a drug of choice while newer drugs are poised to hit the market. Regardless of the drug regimen used for treatment, he stated, clinicians should consider “thinking of treatment as prevention,” because HIV-positive gay men have been shown to transmit hep C sexually.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: HIV, hepatitis C virus, hep C, HCV, coinfection, Incivek, telaprevir, pegylated interferon alfa-2a, ribavirin, aidsmap, Daniel Fierer, Mount Sinai, 64th Annual Meeting of the American Association of the Study of Liver Diseases, AASLD.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dhsd777
    san diego
    California


    oceanblue65
    louisiana
    Louisiana


    Deelight4u
    BROOKLYN
    New York


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.